ROSEN, GLOBAL INVESTOR COUNSEL, Encourages PepGen Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PEPG

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased PepGen Inc. securities between March 7, 2024, and March 3, 2025, due to alleged misleading statements regarding the effectiveness and safety of PGN-EDO51 and the CONNECT2 study [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that PepGen made false and misleading statements about PGN-EDO51's effectiveness and safety, the CONNECT2 study's adequacy for FDA approval, and the overstated clinical and commercial prospects of PGN-EDO51 [5]. - Investors who purchased PepGen securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Investors interested in joining the class action can do so by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must be appointed by August 8, 2025, to represent the class in the lawsuit [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4].